Case report: Bruton tyrosine kinase inhibitor as therapy for chronic lymphocytic leukemia infiltrating a kidney allograft

被引:0
|
作者
Stavart, Louis [1 ,2 ]
Halfon, Matthieu [1 ,2 ]
Dewarrat, Natacha [3 ]
Rotman, Samuel [4 ]
Golshayan, Dela [1 ,2 ,5 ]
机构
[1] Lausanne Univ Hosp CHUV, Transplantat Ctr, Lausanne, Switzerland
[2] Lausanne Univ Hosp CHUV, Transplantat Immunopathol Lab, Lausanne, Switzerland
[3] Lausanne Univ Hosp CHUV, Serv & Cent Lab Hematol, Lausanne, Switzerland
[4] Lausanne Univ Hosp CHUV, Inst Pathol, Lausanne, Switzerland
[5] Univ Lausanne UNIL, Fac Biol & Med, Lausanne, Switzerland
关键词
chronic lymphocytic leukemia; kidney transplantation; Bruton tyrosine kinase inhibitor; acute cellular rejection; case report; B-CELL LYMPHOCYTOSIS; TRANSPLANTATION; IBRUTINIB; LYMPHOMA; PATIENT; DONOR;
D O I
10.3389/fmed.2024.1451264
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The burden of chronic lymphocytic leukemia (CLL) in the prognosis of solid organ transplant (SOT) recipients seems non-negligible. Whether transplanting a patient with previous CLL is safe or what is the optimal monitoring and treatment management after transplantation is still unclear and only based on few case series and reports. Therefore, we aimed to contribute to this understanding by reporting the first documented case of a clinically significant CLL with biopsy-proven infiltration of the kidney allograft and its successful management with a Bruton tyrosine kinase inhibitor (BTKi). We then reviewed the related literature, with a focus on CLL and kidney transplantation. Our main message is that BTKi may represent a safe and effective intervention to prevent the hazardous patient and graft outcomes of CLL in SOT patients.
引用
收藏
页数:7
相关论文
共 50 条
  • [1] Cerebral Invasive Aspergillosis in a Case of Chronic Lymphocytic Leukemia with Bruton Tyrosine Kinase Inhibitor
    Alkharabsheh, Omar
    Alsayed, Alhareth
    Morlote, Diana M.
    Mehta, Amitkumar
    CURRENT ONCOLOGY, 2021, 28 (01) : 837 - 841
  • [2] Acalabrutinib: a bruton tyrosine kinase inhibitor for the treatment of chronic lymphocytic leukemia
    Wolska-Washer, Anna
    Robak, Tadeusz
    EXPERT REVIEW OF HEMATOLOGY, 2022, 15 (03) : 183 - 194
  • [3] The Bruton tyrosine kinase inhibitor ibrutinib with chemoimmunotherapy in patients with chronic lymphocytic leukemia
    Brown, Jennifer R.
    Barrientos, Jacqueline C.
    Barr, Paul M.
    Flinn, Ian W.
    Burger, Jan A.
    Anh Tran
    Clow, Fong
    James, Danelle F.
    Graef, Thorsten
    Friedberg, Jonathan W.
    Rai, Kanti
    O'Brien, Susan
    BLOOD, 2015, 125 (19) : 2915 - 2922
  • [4] Bruton tyrosine kinase inhibition in chronic lymphocytic leukemia
    Maddocks, Kami
    Jones, Jeffrey A.
    SEMINARS IN ONCOLOGY, 2016, 43 (02) : 251 - 259
  • [5] Bruton's tyrosine kinase inhibitor restrains Wnt signaling in chronic lymphocytic leukemia
    Li, Pei-Pei
    Lu, Kang
    Geng, Ling-Yun
    Zhou, Xiang-Xiang
    Li, Xin-Yu
    Wang, Xin
    MOLECULAR MEDICINE REPORTS, 2016, 13 (06) : 4934 - 4938
  • [6] Comparison of Acalabrutinib, A Selective Bruton Tyrosine Kinase Inhibitor, with Ibrutinib in Chronic Lymphocytic Leukemia Cells
    Patel, Viralkumar
    Balakrishnan, Kumudha
    Bibikova, Elena
    Ayres, Mary
    Keating, Michael J.
    Wierda, William G.
    Gandhi, Varsha
    CLINICAL CANCER RESEARCH, 2017, 23 (14) : 3734 - 3743
  • [7] Acalabrutinib: a highly selective, potent Bruton tyrosine kinase inhibitor for the treatment of chronic lymphocytic leukemia
    Ghia, Paolo
    Dlugosz-Danecka, Monika
    Scarfo, Lydia
    Jurczak, Wojciech
    LEUKEMIA & LYMPHOMA, 2021, 62 (05) : 1066 - 1076
  • [8] Bruton Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia Beyond Ibrutinib
    Lasica, Masa
    Tam, Constantine S.
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2021, 35 (04) : 761 - 773
  • [9] Bruton tyrosine kinase inhibitors for the frontline treatment of chronic lymphocytic leukemia
    Banerji, V
    Aw, A.
    Robinson, S.
    Doucette, S.
    Christofides, A.
    Sehn, L. H.
    CURRENT ONCOLOGY, 2020, 27 (06) : E645 - E655
  • [10] Bruton's Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia and Lymphoma
    Varma, Gaurav
    Johnson, Tyler P.
    Advani, Ranjana H.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2016, 14 (07) : 543 - 554